osteonecrosis of the jaw

For more general information, see osteonecrosis of the jaw.

Should I be concerned about osteonecrosis of the jaw?

They want to know whether osteonecrosis of the jaw can be treated and, if so, how likely it is that a person will recover.

Those patients, a small percentage of them, develop osteonecrosis of the jaw.

In the intravenous group, six of every 1,000 developed osteonecrosis of the jaw.

However, a rare condition called osteonecrosis of the jaw has been linked to some bisphosphonates.

There is presently no known prevention for bisphosphonate-associated osteonecrosis of the jaw.

Unlike bisphosphonates, however, denosumab has not been associated with osteonecrosis of the jaw.

Now, what is osteonecrosis of the jaw?

In contrast, safety studies sponsored by the manufacturer reported bisphosphonate-associated osteonecrosis of the jaw rates that were much lower.

Bisphosphonates can cause bone loss in the jaw, known as osteonecrosis of the jaw.

Systematic review: Bisphosphonates and osteonecrosis of the jaw.

A rare complication that has been recently observed in cancer patients being treated with bisphosphonates is osteonecrosis of the jaw.

However, they have exhibited side effect such as the induction of arthralgias and osteonecrosis of the jaw.

"We did a literature search looking for osteonecrosis of the jaw," Dr. Hohneker said.

Osteonecrosis of the jaw is classified based on severity, number of lesions, and lesion size.

Some people using medicines similar to risedronate have developed bone loss in the jaw, also called osteonecrosis of the jaw.

Osteonecrosis of the jaw is rare but serious and involves death of the bone due to lack of blood flow.

A diagnosis of bisphosphonate-associated osteonecrosis of the jaw relies on three criteria:

Osteolysis can also be associated with the radiographic changes seen in a person with bisphosphonate-related osteonecrosis of the jaw.

They examined patients every three months to look for evidence of osteonecrosis of the jaw and compared them with 516 matched patients not on bisphosphonates.

There really isn't even a consistent definition of what osteonecrosis of the jaw is, and the true incidence is unknown."

Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.

This may be a sign of a rare complication of treatment called osteonecrosis of the jaw, or jaw death.

Everyone agrees that the condition, osteonecrosis of the jaw, is an uncommon complication but that its true incidence is not known.